An Aggressive Approach Toward a Case of Refractory Ulcerative Colitis With Uncertain Etiology in the Context of Chronic Myeloid Leukemia

Inflamm Bowel Dis. 2020 Mar 4;26(4):e26-e27. doi: 10.1093/ibd/izaa016.

Authors

Yuanzun Peng^{1

2}, Anusha S Thomas¹, Dongguang Wei³, Dongfeng Tan³, Yinghong Wang¹

Affiliations

¹ Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
² Department of Biosciences, Rice University, Houston, Texas, USA.
³ Department of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

PMID: 32016290
DOI: 10.1093/ibd/izaa016

No abstract available

Keywords: ulcerative colitis; cancer; fecal microbiota transplantation; imatinib.

Publication types

Case Reports
Letter

MeSH terms

Aged
Colitis, Ulcerative / pathology*
Colitis, Ulcerative / therapy*
Colonoscopy
Dasatinib / administration & dosage
Fatal Outcome
Fecal Microbiota Transplantation
Humans
Imatinib Mesylate / administration & dosage
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Male

Substances

Imatinib Mesylate
Dasatinib